Biogen Inc. (BIIB) fundamentals from SEC filings — revenue $9.9B, net margin 13.1%, diluted EPS $8.79 in FY2025. Revenue, margins, EPS and free cash flow, year by year.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $11.0B | $10.2B | $9.8B | $9.7B | $9.9B |
| Net income | $1.6B | $3.0B | $1.2B | $1.6B | $1.3B |
| Net margin | 14.2% | 29.9% | 11.8% | 16.9% | 13.1% |
| Diluted EPS | $10.40 | $20.87 | $7.97 | $11.18 | $8.79 |
| Free cash flow | $3.4B | $1.1B | $1.3B | $2.7B | $2.1B |
Figures are as reported to the SEC (EDGAR companyfacts), in the filer's own fiscal years.
Sign in to PortfolioX for the full analysis — ten years of history, segment and geographic breakdowns, valuation multiples, analyst estimates and filings. · PortfolioX home